<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Several rare, potentially fatal types of hematologic <z:e sem="disease" ids="C0334044" disease_type="Neoplastic Process" abbrv="">dyscrasia</z:e>, such as <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and thrombotic thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (<z:chebi fb="1" ids="18284">TTP</z:chebi>), have been associated with <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The extent to which <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> is the causative factor has not been addressed quantitatively </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We identified 211 published case reports of hematologic <z:e sem="disease" ids="C0334044" disease_type="Neoplastic Process" abbrv="">dyscrasia</z:e> associated with <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> therapy from a MEDLINE search </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed the 91 reports that could be evaluated, using the Bayesian Adverse Reaction Diagnostic Instrument to calculate the posterior probability that <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> caused the hematologic <z:e sem="disease" ids="C0334044" disease_type="Neoplastic Process" abbrv="">dyscrasia</z:e> based on epidemiologic and clinical trial data (prior odds) and case information (likelihood ratio) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The median posterior probability values (and range) for <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and <z:chebi fb="1" ids="18284">TTP</z:chebi> were 0.95 (0.53-0.98), 0.81 (0.57-0.93), 0.86 (0.75-0.96), 0.78 (0.61-0.89), 0.74 (0-0.92) and 1.0 (0.33-1.00) respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The posterior probability was 0.75 or greater in 82 (90%) of the case reports </plain></SENT>
<SENT sid="6" pm="."><plain>INTERPRETATION: This systematic analysis provides stronger evidence to implicate <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> as the causative factor in the various types of hematologic <z:e sem="disease" ids="C0334044" disease_type="Neoplastic Process" abbrv="">dyscrasia</z:e> in most published case reports </plain></SENT>
</text></document>